Evidence that glucose lowering reduces the rates of cardiovascular events and death has not been convincing, although a modest cardiovascular benefit may be observed after a prolonged follow-up period. Furthermore, there is concern that intensive glucose lowering or the use of specific glucose-lowering drugs may be associated with adverse cardiovascular outcomes. Inhibitors of sodium–glucose cotransporter 2 (SGLT2) reduce rates of hyperglycemia in patients with type 2 diabetes by decreasing renal glucose reabsorption, thereby increasing urinary glucose excretion.

Inhibitors of sodium–glucose cotransporter 2 reduce rates of hyperglycemia in patients with type 2 diabetes by decreasing renal glucose reabsorption, thereby increasing urinary glucose excretion [Image: jcomp/Freepik].

Please sign in to read more